Phoenix Wealth Advisors Intellia Therapeutics, Inc. Transaction History

Phoenix Wealth Advisors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	SELL	$34.58 - $46.03 $9,474 - $12,612	-274 Reduced 4.54%	5,755 $234,000
Q1 2023 May 05, 2023	SELL	$33.3 - $44.82 $1,098 - $1,479	-33 Reduced 0.54%	6,029 $224,000
Q4 2022 Feb 06, 2023	SELL	$33.21 - $62.69 $28,394 - $53,599	-855 Reduced 12.36%	6,062 $211,000
Q3 2022 Nov 07, 2022	SELL	$53.92 - $71.7 $22,592 - $30,042	-419 Reduced 5.71%	6,917 $387,000
Q2 2022 Aug 01, 2022	SELL	$38.49 - $76.21 $35,757 - $70,799	-929 Reduced 11.24%	7,336 $380,000
Q1 2022 May 02, 2022	BUY	$58.27 - $118.99 $230,108 - $469,891	3,949 Added 91.5%	8,265 $558,000
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $44,233 - $60,740	-439 Reduced 9.23%	4,316 $510,000
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $21,576 - $28,815	163 Added 3.55%	4,755 $638,000
Q2 2021 Jul 23, 2021	SELL	$60.88 - $161.91 $223,064 - $593,238	-3,664 Reduced 44.38%	4,592 $686,000
Q1 2021 Apr 12, 2021	SELL	$46.59 - $83.68 $115,403 - $207,275	-2,477 Reduced 23.08%	8,256 $661,000
Q4 2020 Feb 05, 2021	BUY	$18.83 - $63.53 $202,102 - $681,867	10,733 New	10,733 $584,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $707M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Phoenix Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Phoenix Wealth Advisors with notifications on news.